Trial Profile
A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- 16 Mar 2021 Results published in the Clinical Cancer Research
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.
- 01 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.